STOCK TITAN
  1. Home
  2. News
  3. FBIO

Fortress Biotech, Inc. - FBIO STOCK NEWS

Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.

Fortress Biotech, Inc. (symbol: FBIO) is a pioneering biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. The company operates through a unique model of establishing subsidiary companies, collectively known as Fortress companies, to promote research, development, and commercialization efforts.

Fortress Biotech leverages its deep expertise in the biopharmaceutical industry and drug development to support its subsidiaries. The company offers funding, management services, and strategic guidance to bolster the success of its Fortress companies. This collaborative approach enables the subsidiaries to focus on breakthrough innovations while benefiting from Fortress Biotech's resources and infrastructure.

The company's diverse product portfolio includes several key products such as Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. These products span across therapeutic areas with a significant focus on dermatology, where Fortress derives the majority of its revenue. Beyond dermatology, the company and its subsidiaries are deeply engaged in biotechnology, pharmaceutical development, oncology, and therapeutics.

Fortress Biotech continuously seeks strategic partnerships, licensing opportunities, joint ventures, and public and private financing to accelerate and support its research and development programs. These collaborations aim to enhance the company's capacity to bring novel treatments to market and address unmet medical needs.

For the latest updates and events, including financial results discussions and corporate updates, Fortress Biotech frequently engages with its stakeholders through conference calls and press releases.

For more information or media inquiries, please contact:
Jaclyn Jaffe, Fortress Biotech, Inc.: (781) 652-4500, ir@fortressbiotech.com
Tony Plohoros, 6 Degrees: (908) 591-2839, tplohoros@6degreespr.com

News

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
News

Fortress Biotech to Participate in 36th Annual ROTH Conference

Rhea-AI Summary
Fortress Biotech, Inc. (NASDAQ: FBIO) announced that Lindsay A. Rosenwald, M.D., will participate in a fireside chat at the 36th Annual ROTH Conference. The company focuses on acquiring, developing, and commercializing therapeutic products. The webcast will be available on their website for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences
-
News

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Rhea-AI Summary
Journey Medical Corporation (DERM) presents positive Phase 1 clinical trial results for DFD-29 at AAD Annual Meeting. The trial showed no significant safety issues and demonstrated the potential for DFD-29 to treat rosacea effectively. The New Drug Application for DFD-29 is under review by the U.S. FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
clinical trial
News

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Rhea-AI Summary
A Phase 1 CAR T cell therapy trial at City of Hope for glioblastoma shows promising results. The trial, the largest reported for solid tumors, used CAR T cells targeting IL13Rα2. Half of the patients had stable disease for at least two months, with two partial responses and two complete responses. The therapy was well-tolerated, with a median overall survival of eight months. Patients receiving optimized doses had a median survival of 10.2 months, surpassing the expected rate for recurrent glioblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
clinical trial
-
News

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Rhea-AI Summary
Cyprium Therapeutics, a subsidiary of Fortress Biotech, receives a $4.1 million grant from NIH to advance AAV-ATP7A gene therapy in conjunction with CUTX-101 for Menkes disease treatment. The combination shows promising results in preclinical studies, aiming to be the first FDA-approved treatment for this rare pediatric disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
none
-
News

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Rhea-AI Summary
Journey Medical Corporation (DERM) submits NDA for DFD-29, a potential best-in-class oral medication for rosacea treatment, supported by positive Phase 3 clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
News

Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Fortress Biotech, Inc. (FBIO) announced the closing of a registered direct offering, issuing 3,303,305 shares of common stock and warrants at a combined offering price of $3.33 per share, resulting in gross proceeds of approximately $11.0 million. The transaction closed on January 3, 2024, with Roth Capital Partners acting as the exclusive placement agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
offering
-
News

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a credit facility with SWK Holdings Corporation for up to $20 million to support general corporate purposes and potential launch of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
none
-
News

Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) has entered into a definitive agreement for the issuance and sale of 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $11.0 million. Fortress expects to use the net proceeds from the offering for its operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, license or acquisition of new products, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.62%
Tags
offering
News

Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics

Rhea-AI Summary
Sentynl Therapeutics, Inc. (Sentynl) has acquired worldwide proprietary rights and U.S. FDA documents for CUTX-101, a potential FDA-approved treatment for Menkes disease. The rolling submission of the New Drug Application to the FDA is ongoing and expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none

FAQ

What is the current stock price of Fortress Biotech (FBIO)?

The current stock price of Fortress Biotech (FBIO) is $1.61 as of November 22, 2024.

What is the market cap of Fortress Biotech (FBIO)?

The market cap of Fortress Biotech (FBIO) is approximately 43.6M.

What does Fortress Biotech, Inc. do?

Fortress Biotech acquires, develops, and commercializes innovative pharmaceutical and biotechnology products.

What are Fortress companies?

Fortress companies are subsidiaries established by Fortress Biotech to focus on specialized research, development, and commercialization of biotech products.

What products does Fortress Biotech offer?

Fortress Biotech's portfolio includes Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm.

How does Fortress Biotech support its subsidiaries?

Fortress Biotech provides funding, management services, and strategic guidance to support the growth and success of its subsidiaries.

What is the primary revenue source for Fortress Biotech?

The majority of Fortress Biotech's revenue comes from its dermatology segment.

Does Fortress Biotech engage in partnerships?

Yes, Fortress Biotech frequently seeks licensing, partnerships, joint ventures, and public and private financings to support its development programs.

Which therapeutic areas does Fortress Biotech focus on?

Fortress Biotech and its subsidiaries focus on dermatology, biotechnology, pharmaceutical development, oncology, and therapeutics.

How can I get the latest news on Fortress Biotech?

You can stay updated by following Fortress Biotech's press releases and participating in their conference calls.

Who can I contact for more information about Fortress Biotech?

For more information, contact Jaclyn Jaffe at Fortress Biotech or Tony Plohoros at 6 Degrees.

Where can I find financial updates from Fortress Biotech?

Financial updates are provided through conference calls and press releases hosted by Fortress Biotech.

Stock FBIO logo
Fortress Biotech, Inc.

Nasdaq:FBIO

FBIO Rankings

#4929 Ranked by Market Cap
N/A Ranked by Dividends

FBIO Stock Data

43.62M
21.76M
21.21%
15.78%
9.51%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BAY HARBOR ISLANDS